Art v 1 IgE epitopes of patients and humanized mice are conformational.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
10 2022
Historique:
received: 16 04 2021
revised: 31 03 2022
accepted: 21 04 2022
pubmed: 24 6 2022
medline: 12 10 2022
entrez: 23 6 2022
Statut: ppublish

Résumé

Worldwide, pollen of the weed mugwort (Artemisiavulgaris) is a major cause of severe respiratory allergy, with its major allergen, Art v 1, being the key pathogenic molecule for millions of patients. Humanized mice transgenic for a human T-cell receptor specific for the major Art v 1 T-cell epitope and the corresponding HLA have been made. We sought to characterize IgE epitopes of Art v 1-sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy. Four overlapping peptides incorporating surface-exposed amino acids representing the full-length Art v 1 sequence were synthesized and used to search for IgE reactivity to sequential epitopes. For indirect mapping, peptide-specific rabbit antibodies were raised to block IgE against surface-exposed epitopes on folded Art v 1. IgE reactivity and basophil activation studies were performed in clinically defined mugwort-allergic patients. Secondary structure of recombinant (r) Art v 1 and peptides was determined by circular dichroism spectroscopy. Mugwort-allergic patients and humanized mice sensitized by allergen inhalation showed IgE reactivity and/or basophil activation mainly to folded, complete Art v 1 but not to unfolded, sequential peptide epitopes. Blocking of allergic patients' IgE with peptide-specific rabbit antisera identified a hitherto unknown major conformational IgE binding site in the C-terminal Art v 1 domain. Identification of the new major conformational IgE binding site on Art v 1, which can be blocked with IgG raised against non-IgE reactive Art v 1 peptides, is an important basis for the development of a hypoallergenic peptide vaccine for mugwort allergy.

Sections du résumé

BACKGROUND
Worldwide, pollen of the weed mugwort (Artemisiavulgaris) is a major cause of severe respiratory allergy, with its major allergen, Art v 1, being the key pathogenic molecule for millions of patients. Humanized mice transgenic for a human T-cell receptor specific for the major Art v 1 T-cell epitope and the corresponding HLA have been made.
OBJECTIVE
We sought to characterize IgE epitopes of Art v 1-sensitized patients and humanized mice for molecular immunotherapy of mugwort allergy.
METHODS
Four overlapping peptides incorporating surface-exposed amino acids representing the full-length Art v 1 sequence were synthesized and used to search for IgE reactivity to sequential epitopes. For indirect mapping, peptide-specific rabbit antibodies were raised to block IgE against surface-exposed epitopes on folded Art v 1. IgE reactivity and basophil activation studies were performed in clinically defined mugwort-allergic patients. Secondary structure of recombinant (r) Art v 1 and peptides was determined by circular dichroism spectroscopy.
RESULTS
Mugwort-allergic patients and humanized mice sensitized by allergen inhalation showed IgE reactivity and/or basophil activation mainly to folded, complete Art v 1 but not to unfolded, sequential peptide epitopes. Blocking of allergic patients' IgE with peptide-specific rabbit antisera identified a hitherto unknown major conformational IgE binding site in the C-terminal Art v 1 domain.
CONCLUSIONS
Identification of the new major conformational IgE binding site on Art v 1, which can be blocked with IgG raised against non-IgE reactive Art v 1 peptides, is an important basis for the development of a hypoallergenic peptide vaccine for mugwort allergy.

Identifiants

pubmed: 35738928
pii: S0091-6749(22)00701-1
doi: 10.1016/j.jaci.2022.04.031
pii:
doi:

Substances chimiques

Allergens 0
Amino Acids 0
Antigens, Plant 0
Epitopes, T-Lymphocyte 0
Immune Sera 0
Immunoglobulin G 0
Peptides 0
Plant Proteins 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

920-930

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Maja Zabel (M)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Milena Weber (M)

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Bernhard Kratzer (B)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Cordula Köhler (C)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Beatrice Jahn-Schmid (B)

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Gabriele Gadermaier (G)

Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.

Pia Gattinger (P)

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Urška Bidovec-Stojkovič (U)

Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.

Peter Korošec (P)

Laboratory for Clinical Immunology and Molecular Genetics, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.

Ursula Smole (U)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Gert Wurzinger (G)

Pulmological Outpatient Clinic, LKH, Graz, Austria.

Kuan-Wei Chen (KW)

Center for Gene and Cellular Therapies in Treatment of Cancer - OncoGen Center, Pius Brinzeu County Clinical Emergency Hospital, Timișoara, Romania.

Carmen Bunu Panaitescu (CB)

Center for Gene and Cellular Therapies in Treatment of Cancer - OncoGen Center, Pius Brinzeu County Clinical Emergency Hospital, Timișoara, Romania; Department of Functional Sciences, Physiology, Center of Immuno-Physiology and Biotechnologies (CIFBIOTEH), Victor Babeș University of Medicine and Pharmacy, Timișoara, Romania.

Ludger Klimek (L)

Center for Rhinology and Allergology, Wiesbaden, Germany.

Isabel Pablos (I)

Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.

Katarzyna Niespodziana (K)

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner University, Krems, Austria.

Alina Neunkirchner (A)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Walter Keller (W)

Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.

Rudolf Valenta (R)

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner University, Krems, Austria; Laboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, Russia; NRC Institute of Immunology FMBA of Russia, Moscow, Russia. Electronic address: rudolf.valenta@meduniwien.ac.at.

Winfried F Pickl (WF)

Institute of Immunology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner University, Krems, Austria. Electronic address: winfried.pickl@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH